IP Library Granted Patent US 10,035,769
Granted Patent B2
US 10,035,769 · App. 15/366,590 · Granted Jul 31, 2018

Quaternary heteroatom containing compounds

Inventors: Brian M. Stoltz (San Marino, CA); Scott C. Virgil (Pasadena, CA); David E. White (Wayne, PA); Taiga Yurino (Kyoto, JP); Yiyang Liu (Pasadena, CA); Douglas C. Behenna (Laguna Niguel, CA); Douglas Duquette (Los Angeles, CA); Christian Eidamshaus (Pasadena, CA)
Assignee: California Institute of Technology
C07D211/78C07D207/27C07D207/277C07D211/76C07D211/90C07D211/96C07D223/10C07D265/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,035,769
App. No.
15/366,590
Granted
Jul 31, 2018
Kind
B2
Abstract

The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II): comprising treating a compound of Formula (I): with a transition metal catalyst and under alkylation conditions as valence and stability permit.

Claims (49)

1. A method for the preparation of a compound of Formula (II):

comprising treating a compound of Formula (I):

with a transition metal catalyst under alkylation conditions, wherein the transition metal catalyst is a palladium catalyst comprising Pd 2 (dba) 3 or Pd 2 (pmdba) 3 ; or the transition metal catalyst further comprises (R)—(CF 3 ) 3 -tBuPHOX, (R)-tBuPHOX, (S)—(CF 3 ) 3 -tBuPHOX, or (S)-tBuPHOX;

wherein, as valence and stability permit,

ring B represents an optionally substituted heterocycle;

X is a heteroatom;

R 1 is selected from optionally substituted alkyl, alkenyl, alkynyl, carbocyclyl, heterocycle, aryl, heteroaryl, and halogen;

R 2 , R 3 , R 4 , R 5 , R 12 , R 13 , R 14 , and R 15 are independently selected at each occurrence from hydrogen, hydroxyl, halogen, nitro, alkyl, alkenyl, alkynyl, cyano, carboxyl, sulfate, amino, alkoxy, alkylamino, alkylthio, hydroxyalkyl, alkoxyalkyl, aminoalkyl, thioalkyl, ether, thioether, ester, amide, thioester, carbonate, carbamate, urea, sulfonate, sulfone, sulfoxide, sulfonamide, acyl, acyloxy, acylamino, aryl, heteroaryl, carbocyclyl, heterocyclyl, aralkyl, aralkyloxy, hetaralkyl, carbocyclylalkyl, and heterocyclylalkyl.

2. The method of claim 1 , for preparation of a compound of Formula (IV):

comprising treating a compound of Formula (III):

with a transition metal catalyst under alkylation conditions, wherein, as valence and stability permit,

X is selected from NR 6 — and —O—;

Z is selected from —C(O)— and CR 7 R 7 —;

A is independently selected at each occurrence from —CR 8 R 8 — and —NR 9 —;

W is absent or selected from —O—, —NR 10 —, and —CR 8 R 8 — and —NR 9 —;

R 1 is selected from halogen and an optionally substituted group selected from alkyl, carbocyclyl, carbocyclylalkyl, cyanoalkyl, aralkyl, heteroaralkyl, hydroxyalkyl, haloalkyl, acylalkyl, alkoxycarbonylalkyl, and aryloxycarbonylalkyl;

R 2 , R 12 , R 7 , R 8 , and R 11 are independently selected at each occurrence from hydrogen, hydroxyl, halogen, haloalkyl, alkyl, cyano, amino, alkoxy, alkylthio, amido, carbocyclyl, and haloalkyl;

R 3 , R 4 , R 5 , R 13 , R 14 , and R 15 are independently selected at each occurrence from hydrogen, halogen, haloalkyl, cyano, alkyl, alkoxy, alkylthio, amide, amine, aryloxy, and aralkyloxy;

R 6 , R 9 and R 10 are independently selected at each occurrence from hydrogen, hydroxyl and optionally substituted alkyl, alkoxy, alkylthio, aryloxy, carbocyclyl, aryl, heteroaryl, aralkyl, heteroaralkyl, aralkyloxy, heteroaryloxy, acyl, arylcarbonyl, aralkylcarbonyl, acyloxy, alkylsulfonyl, arylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, and amido; and

n is 0-3.

3. The method of claim 2 , wherein:

R 1 is selected from halogen, alkyl, optionally substituted aralkyl, optionally substituted alkoxycarbonylalkyl, optionally substituted cyanoalkyl, and optionally substituted hydroxyalkyl; and

R 6 , R 9 , and R 10 are independently selected at each occurrence from optionally substituted aralkyloxy, aralkoxycarbonyl, heteroaryloxy, acyl, arylcarbonyl, aralkylcarbonyl, arylsulfonyl, alkoxycarbonyl, and aryloxycarbonyl.

4. The method of claim 3 , wherein:

X is —NR 6 —;

Z is selected from —C(O)— and —CR 7 R 7 —;

A at each occurrence is —CR 8 R 8 —;

W is selected from —NR 10 — and —CR 11 R 11 —; and

n is 0-2.

5. The method of claim 4 , wherein Z is —CR 7 R 7 —.

6. The method of claim 4 , wherein W is —NR 10 —.

7. The method of claim 2 , wherein n is 1.

8. The method of claim 3 , wherein:

X is —O—;

Z is selected from —C(O)— and —CR 7 R 7 —;

A at each occurrence is —CR 8 R 8 —;

W is selected from —NR 10 —, and —CR 11 R 11 —; and

n is 0-2.

9. The method of claim 8 , wherein Z is —CR 7 R 7 —.

10. The method of claim 8 , wherein W is —NR 10 —.

11. The method of claim 2 , wherein the transition metal catalyst is a palladium catalyst.

12. The method of claim 11 , wherein the transition metal catalyst is selected from Pd 2 (dba) 3 and Pd 2 (pmdba) 3 .

13. The method of claim 11 , wherein the palladium catalyst is used in an amount selected from 1 mol % to 20 mol % relative to the substrate.

14. The method of claim 13 , wherein the palladium catalyst is used in an amount selected from 2 mol % to 8 mol % relative to the substrate.

15. The method of claim 2 , wherein the method further comprises a chiral ligand.

16. The method of claim 15 , wherein the chiral ligand is a phosphine ligand.

17. The method of claim 16 , wherein the chiral ligand is selected from (R)—(CF 3 ) 3 -tBuPHOX, (R)-tBuPHOX, (S)—(CF 3 ) 3 -tBuPHOX, and (S)-tBuPHOX.

18. The method of claim 15 , wherein the chiral ligand is used in an amount selected from 2.5 mol % to 13 mol % relative to the substrate.

19. A method of preparing a pharmaceutical compound, comprising preparing a compound of Formula (II) according to the method of claim 1 , and preparing the pharmaceutical compound from the compound of Formula (II).

Assignments (2)
CONFIRMATORY LICENSE Recorded Feb 10, 2017
From: CALIFORNIA INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 041220/0387 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2016
From: STOLTZ, BRIAN M.; VIRGIL, SCOTT C.; WHITE, DAVID E.; YURINO, TAIGA; LIU, YIYANG; DUQUETTE, DOUGLAS; EIDAMSHAUS, CHRISTIAN; BEHENNA, DOUGLAS C.
To: CALIFORNIA INSTITUTE OF TECHNOLOGY
Reel/Frame 040495/0001 →
Continuity (4)
Continuation 13797736 · Mar 12, 2013
Continuation In Part 13531485 · Jun 22, 2012
Provisional Application 61501054 · Jun 24, 2011
Related Publication 20170137382A1 · May 18, 2017